Bank of America
SLNO

Bank of America’s Soleno Therapeutics SLNO Stock Holding History

Bank of America’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,000
Closed -$2.5M – 8642
2025
Q1 		$2.5M Buy
+35,000
New +$1.7M ﹤0.01% 4480

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Bank of America's SLNO Position: Q1 2026 in Review

Bank of America increased its Soleno Therapeutics (SLNO) stake by 111% in Q1 2026, buying an estimated $9.07M and bringing the position to 439,902 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2642.

Bank of America first reported a position in SLNO in Q3 2016 and has held it in 27 quarters since. The position peaked at $30.7M in Q1 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Bank of America held 439,902 shares of Soleno Therapeutics worth $14.7M as of Q1 2026.
  • Bank of America bought 231,307 Soleno Therapeutics shares in Q1 2026, an estimated $9.07M.
  • Soleno Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2642 holding.
  • Bank of America first reported a position in Soleno Therapeutics in Q3 2016 and has held it in 27 quarters since.
  • Bank of America's Soleno Therapeutics position peaked at $30.7M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.